Blood expression data from psoriasis patients treated with secukinumab. Blood expression data from psoriasis patients treated with secukinumab

Psoriasis is a common chronic inflammatory skin disease where IκBζ is known to play an important role by mediating IL-17A-driven effects. However, the molecular mechanism by which IL-17A regulates IκBζ expression is not known. We assessed global gene expression my microarray analysis to explore the molecular transformation in blood samples from psoriatic patients during anti-IL-17A (secukinumab) treatment. Overall design: Blood samples were taken from psoriatic patients before secukinumab treatment (day 0) and at day 4, 14, 42 and 84 during secukinumab treatment. PBMCs were isolated from the blood and RNA extracted and used for microarray analysis.